Your browser is no longer supported. Please, upgrade your browser.
Settings
VRTX [NASD]
Vertex Pharmaceuticals Incorporated
IndexS&P 500 P/E22.01 EPS (ttm)8.34 Insider Own0.10% Shs Outstand257.88M Perf Week-0.98%
Market Cap47.32B Forward P/E13.76 EPS next Y13.34 Insider Trans10.43% Shs Float253.83M Perf Month1.46%
Income2.18B PEG2.15 EPS next Q3.45 Inst Own93.60% Short Float1.88% Perf Quarter-8.17%
Sales7.13B P/S6.64 EPS this Y128.00% Inst Trans0.17% Short Ratio3.06 Perf Half Y-12.00%
Book/sh36.96 P/B4.97 EPS next Y4.73% ROA17.90% Target Price253.91 Perf Year-15.82%
Cash/sh27.00 P/C6.80 EPS next 5Y10.25% ROE23.90% 52W Range176.36 - 242.99 Perf YTD-22.32%
Dividend- P/FCF24.66 EPS past 5Y45.30% ROI26.40% 52W High-24.45% Beta0.60
Dividend %- Quick Ratio4.50 Sales past 5Y43.20% Gross Margin87.90% 52W Low4.10% ATR4.65
Employees3400 Current Ratio4.60 Sales Q/Q29.00% Oper. Margin37.20% RSI (14)45.71 Volatility2.82% 2.48%
OptionableYes Debt/Eq0.00 EPS Q/Q29.80% Profit Margin30.50% Rel Volume0.71 Prev Close186.24
ShortableYes LT Debt/Eq0.05 EarningsNov 02 AMC Payout0.00% Avg Volume1.56M Price183.59
Recom2.00 SMA20-1.84% SMA50-0.45% SMA200-8.50% Volume1,113,628 Change-1.42%
Nov-19-21Initiated BMO Capital Markets Market Perform $202
Nov-19-21Downgrade Piper Sandler Overweight → Neutral $323 → $218
Sep-09-21Downgrade Stifel Buy → Hold $244 → $213
Sep-07-21Downgrade Morgan Stanley Equal-Weight → Underweight $202
Jul-20-21Downgrade SVB Leerink Mkt Perform → Underperform $170
Jul-19-21Resumed Wolfe Research Outperform $252
Jul-01-21Initiated Raymond James Mkt Perform
Jun-11-21Downgrade Daiwa Securities Outperform → Neutral $210
Feb-23-21Upgrade Robert W. Baird Neutral → Outperform $220 → $252
Feb-02-21Reiterated H.C. Wainwright Buy $315 → $275
Dec-30-20Initiated Daiwa Securities Outperform $250
Nov-30-20Upgrade RBC Capital Mkts Sector Perform → Outperform $247 → $267
Nov-20-20Initiated Bernstein Outperform $225
Oct-28-20Initiated UBS Buy $287
Jul-31-20Reiterated H.C. Wainwright Buy $295 → $315
Jul-08-20Downgrade Morgan Stanley Overweight → Equal-Weight $300
Apr-30-20Reiterated H.C. Wainwright Buy $270 → $295
Apr-28-20Downgrade RBC Capital Mkts Outperform → Sector Perform $250 → $260
Mar-04-20Initiated Barclays Overweight $271
Jan-31-20Downgrade Robert W. Baird Outperform → Neutral $210 → $230
Nov-26-21 07:42AM  
Nov-23-21 12:01PM  
Nov-20-21 07:00AM  
Nov-19-21 06:00AM  
Nov-17-21 11:15AM  
10:45AM  
09:53AM  
Nov-15-21 09:04AM  
Nov-12-21 07:27AM  
Nov-11-21 06:47AM  
06:00AM  
Nov-09-21 01:41PM  
Nov-08-21 10:17AM  
Nov-05-21 10:20AM  
06:00AM  
Nov-04-21 02:44PM  
10:08AM  
09:10AM  
07:37AM  
06:31AM  
06:05AM  
06:00AM  
Nov-03-21 10:48AM  
12:00AM  
Nov-02-21 05:15PM  
04:56PM  
04:01PM  
06:52AM  
Nov-01-21 12:09PM  
11:32AM  
09:41AM  
05:51AM  
Oct-30-21 06:00AM  
Oct-29-21 11:27AM  
08:32AM  
Oct-28-21 11:40AM  
10:46AM  
07:01AM  
Oct-27-21 12:07PM  
11:15AM  
10:14AM  
09:25AM  
08:36AM  
07:25AM  
Oct-26-21 05:45PM  
03:03PM  
09:21AM  
09:00AM  
Oct-25-21 11:06AM  
Oct-22-21 08:00AM  
07:05AM  
05:55AM  
Oct-21-21 11:04AM  
Oct-20-21 05:45PM  
01:23PM  
06:00AM  
Oct-19-21 11:30AM  
11:08AM  
10:00AM  
08:58AM  
08:50AM  
08:00AM  
Oct-18-21 05:46PM  
07:30AM  
05:51AM  
Oct-17-21 09:01AM  
Oct-16-21 06:04AM  
Oct-15-21 02:12PM  
05:55AM  
Oct-13-21 05:45PM  
12:10PM  
07:15AM  
06:00AM  
Oct-12-21 02:18PM  
11:40AM  
Oct-11-21 11:11AM  
10:17AM  
Oct-09-21 10:15AM  
Oct-08-21 05:52AM  
Oct-07-21 05:45PM  
10:23AM  
06:00AM  
Oct-06-21 09:00AM  
Oct-05-21 11:00AM  
Oct-04-21 05:53PM  
10:56AM  
Oct-03-21 06:55AM  
Sep-30-21 05:45PM  
11:30AM  
06:17AM  
06:05AM  
05:51AM  
Sep-29-21 11:33AM  
Sep-28-21 11:45AM  
09:13AM  
05:55AM  
05:51AM  
Sep-27-21 01:24PM  
Sep-25-21 06:20AM  
Sep-24-21 08:53AM  
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; Mammoth Biosciences; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sachdev AmitEVP, Chief Patient OfficerNov 15Sale187.19519,54731,928Nov 16 04:07 PM
Arbuckle Stuart AEVP, COONov 15Sale187.26356241,103Nov 16 04:05 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 15Sale187.22346,36533,589Nov 16 04:04 PM
Kewalramani ReshmaCEO & PresidentAug 19Buy195.6510,0001,956,49273,754Aug 23 08:30 AM
SACHS BRUCE IDirectorAug 02Buy197.9115,0002,968,65041,210Aug 04 04:05 PM
Bhatia Sangeeta N.DirectorJun 02Sale209.69559117,2165,191Jun 04 04:03 PM
Arbuckle Stuart AEVP, Chief Comm & Ops OfficerMay 17Sale216.4110923,58941,103May 19 04:04 PM
ALTSHULER DAVIDEVP, Global Research and CSOMay 17Sale216.367917,09333,589May 19 04:02 PM
Sanna BastianoEVP, Cell & Genetic TherapiesMay 17Sale216.3411224,23034,108May 19 04:10 PM
Sachdev AmitEVP, Chief Patient OfficerMay 17Sale216.35459,73640,133May 19 04:08 PM
Sanna BastianoEVP, Cell & Genetic TherapiesMay 03Sale218.43960209,69134,108May 05 09:23 PM
Sachdev AmitEVP, Chief Patient OfficerApr 27Option Exercise86.523,884336,04444,017Apr 29 04:03 PM
Sachdev AmitEVP, Chief Patient OfficerApr 27Sale216.063,884839,19340,133Apr 29 04:03 PM
Sanna BastianoEVP, Cell & Genetic TherapiesApr 05Sale214.141,686361,04635,834Apr 07 04:04 PM
Liu JoySVP, General CounselMar 05Sale209.695,1411,078,0188,253Mar 08 04:10 PM
Silva Paul MSVP & Chief Accounting OfficerMar 01Sale211.452,782588,2559,884Mar 02 04:07 PM
Silva Paul MSVP & Chief Accounting OfficerFeb 25Sale213.471,080230,55114,884Feb 26 04:23 PM
Sachdev AmitEVP, Chief Patient OfficerFeb 25Sale213.423,586765,30740,133Feb 26 04:20 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffFeb 25Sale213.383,028646,12530,837Feb 26 04:18 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerFeb 25Sale213.543,634775,98941,103Feb 26 04:07 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 25Sale213.393,028646,13933,589Feb 26 04:03 PM
Silva Paul MSVP & Chief Accounting OfficerFeb 18Sale211.834,295909,82816,828Feb 19 04:21 PM
Sachdev AmitEVP, Chief Patient OfficerFeb 18Sale211.839,2641,962,36646,665Feb 19 04:20 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffFeb 18Sale211.837,8251,657,55636,281Feb 19 04:18 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerFeb 18Sale211.827,8251,657,48147,635Feb 19 04:08 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 18Sale211.837,8251,657,59039,033Feb 19 04:05 PM
Sachdev AmitEVP, Chief Patient OfficerFeb 11Sale210.554,460939,06863,542Feb 16 04:20 PM
Silva Paul MSVP & Chief Accounting OfficerFeb 11Sale210.571,498315,43723,863Feb 16 04:24 PM
Sanna BastianoEVP, Cell & Genetic TherapiesFeb 11Sale210.561,686355,01238,864Feb 16 04:22 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffFeb 11Sale210.564,318909,17950,346Feb 16 04:15 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerFeb 11Sale210.555,1561,085,59361,700Feb 16 04:07 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 11Sale210.545,2831,112,27453,098Feb 16 04:02 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffFeb 05Option Exercise86.521,930166,98459,157Feb 09 07:44 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffFeb 05Sale215.001,930414,95057,227Feb 09 07:44 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerFeb 03Option Exercise86.521,554134,45271,511Feb 05 04:43 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffFeb 03Option Exercise86.5240034,60857,627Feb 05 04:52 PM
Parini MichaelEVP, Chief Adm, Leg & BD OffFeb 03Sale216.5640086,62457,227Feb 05 04:52 PM
Arbuckle Stuart AEVP, Chief Commercial OfficerFeb 03Sale213.741,554332,14669,957Feb 05 04:43 PM